Natco Pharma share price shed in the early trade on November 24 following the company received seven observations from United State Food and Drug Administration (USFDA).
At 09:19am, Natco Pharma was quoting at Rs 852.15, down Rs 12.25, or 1.42 percent, on the BSE.
The USFDA concluded the inspection at company's Manali, Chennai, Active Pharmaceutical Ingredients (API) unit, which was conducted from November 17-21, 2025.
On conclusion of the inspection, the company received seven observations in the Form-483.
The company believes that the observations are procedural in nature and confident to address these observations comprehensively.
Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally, it said.
Catch all the market action on our live blog
Broking house ICICI Securities in its report dated November 15, has retained 'reduce' rating with a revised target price of Rs 750.
The company had posted 23 percent fall in its September quarter net profit at Rs 518.40 crore versus Rs 677.30 crore, YoY.
In the previous trading session, the share closed at Rs 864.40, down Rs 4.90, or 0.56 percent.
The share touched a 52-week high of Rs 1,504.00 and a 52-week low of Rs 660.05 on 10 December, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 42.53 percent below its 52-week high and 30.96 percent above its 52-week low.
The market capitalisation of the company stands at Rs 15,482.26 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
